Phase 2 Post-Transplant Lymphoproliferative Disorder Clinical Trials
5 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–5 of 5 trials
Recruiting
Phase 2
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Reem Karmali34 enrolled1 locationNCT06723457
Recruiting
Phase 1Phase 2
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Post-Transplant Lymphoproliferative Disorder
Washington University School of Medicine12 enrolled1 locationNCT06040320
Recruiting
Phase 2
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder
Timothy Voorhees28 enrolled4 locationsNCT05786040
Recruiting
Phase 1Phase 2
EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation
Post-Transplant Lymphoproliferative DisorderEBV-DNA Viremia
Daihong Liu18 enrolled1 locationNCT07438067
Recruiting
Phase 1Phase 2
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Post-Transplant Lymphoproliferative DisorderEpstein-Barr Virus Infection
Daihong Liu18 enrolled1 locationNCT07368634